In addition to NLRP3, it has been found that AIM2 is highly expressed in B cells from SLE patients, promoting B-cell differentiation by regulating the Bcl-6–Blimp-1 axis; this provides a novel target for SLE treatment (32). This evidence concerns the gene PRDM1 and systemic lupus erythematosus.